Articles Tagged With:
-
Sulbactam-Durlobactam for Treatment of Bacterial Pneumonia
Sulbactam-durlobactam is non-inferior to colistin in the treatment of serious bacterial infections caused by Acinetobacter baumannii-calcoaceticus complex organisms.
-
Bartonella quintana in New York City
Six cases of Bartonella quintana infection were detected in New York City in individuals experiencing homelessness; four required cardiac valve replacement for endocarditis.
-
Prevention of Ventilator-Associated Pneumonia
Administration of amikacin for three days beginning early in mechanically ventilated patients significantly reduces ventilator-associated pneumonia.
-
APIC, SHEA Say Mandate COVID Shots for HCWs
Although the federal requirement that healthcare workers be vaccinated against COVID-19 has been lifted, a statement signed by the nation’s leading infection control groups and various other associations emphasizes the importance of mandatory vaccination by individual hospitals.
-
APIC Continues Fight, Urging CMS to Upgrade ICP in Nursing Homes
The Association for Professionals in Infection Control and Epidemiology continues to vigorously argue that the Centers for Medicare and Medicaid Services needs to significantly upgrade infection control in nursing homes.
-
Welcome to the Briar Patch: Ethics of Antibiotic Stewardship
Applying ethical concepts to infection control and infectious disease issues, helps infection preventionists and infectious disease physicians reframe problems and develop “moral resilience” to make tough choices, said Olivia Kates, MD, MA, an infectious disease professor and director of research ethics at Johns Hopkins University in Baltimore.
-
Adjunctive Dexamethasone Is Not Beneficial for HIV Patients with Tuberculous Meningitis
A randomized, placebo-controlled clinical trial in human immunodeficiency virus-positive adults with tuberculous meningitis found no benefit for adjunctive dexamethasone in survival or risk of neurologic immune reconstitution inflammatory syndrome (IRIS). Side effects were similar to placebo.
-
Healing HCWs — Including IPs — Is a National Priority for CDC, NIOSH
Burnout among all stripes of healthcare workers — including infection preventionists — has become a dire situation warranting national action. Accordingly, the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health have released new research and emphasized available resources to raise awareness for an ambitious “system change” in healthcare delivery.
-
Comparing the Safety of Cefepime and Piperacillin-Tazobactam: The ACORN Trial
Qian and colleagues conducted a pragmatic, open-label, randomized clinical trial to determine whether the empiric use of piperacillin-tazobactam or cefepime affects the risk of acute kidney injury (AKI) or neurological dysfunction in patients hospitalized for sepsis. The study showed no significant difference in the incidence of AKI between groups, but rates of neurological dysfunction were slightly higher in patients treated with cefepime.
-
CDC Draft Revamps Airborne Precautions, Calls for N95s
New draft patient isolation guidelines recently approved by advisors to the Centers for Disease Control and Prevention call for scrapping the “outdated dichotomy” of droplet/airborne precautions in favor of a “continuum” approach to stop transmission through the air.